FOXP3 and colitis: However, one study showed that only injection of OVA-specific Tr1 cells, and not FOXP3+ Tregs, multiple weeks after colitis onset resolved intestinal inflammation which indicates that mainly Tr1 cells are able to expand in vivo to control inflammation and ongoing disease and ongoing disease (90).